Abstract:

No standard therapy is recommended for elderly multicentric Castleman's disease (MCD) patients who failed to the first-line treatment or relapsed. Lenalidomide has been reported to be effective for relapsed/refractory MCD in foreign countries, but its effect on this disease has been rarely reported in China. We reported two elderly patients with relapsed/refractory MCD presented with long-term remission after second-line treatment with lenalidomide, and reviewed relevant literature, then suggested that lenalidomide showed encouraging efficacy in patients with MCD, which may be an attractive alternative for relapsed/refractory MCD. Elderly patients with MCD may be more likely to benefit from lenalidomide-based treatment because of the poor general condition and various complications.

Key words: Multicentric Castleman's disease, Aged, Lenalidomide, Recurrence, Refractory diseases

摘要：

一线治疗失败或复发的老年多中心型Castleman病（MCD）患者尚无标准的治疗方案，国外文献报道来那度胺对于复发/难治的MCD有一定疗效，但中文文献报道较少。本文报道2例来那度胺二线治疗老年复发/难治的MCD患者后取得长期缓解，并对相关文献进行复习，提示来那度胺治疗MCD有效，可以作为治疗复发/难治MCD的一种选择。老年MCD患者本身可能一般状况差，存在各种合并症，从而可能从以来那度胺为基础的治疗方案中获益。

关键词: 多中心型Castleman病, 老年人, 来那度胺, 复发, 难治病